Physician profile
Dylan L Steer
NPI 1437154978
$47,973.09
in general payments reported to CMS, 2019-2025
14 companies · $44.64 in 2025
The $44.64 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $60.60 · 2021: $118 · 2022: $47.66 · 2023: $14K · 2024: $34K · 2025: $44.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $46K · Food and Beverage: $1,551 · Education: $4.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $46,191.91 |
| Food and Beverage | $1,551.06 |
| Education | $4.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $34,536.96 | 2021-2024 | |
| Modulated Imaging, INC. | $12,725.67 | 2022-2024 | Clarifi Imaging System |
| Astrazeneca Pharmaceuticals LP | $277.34 | 2024 | |
| Kyowa Kirin, INC. | $104.75 | 2024 | |
| Outset Medical INC | $100.82 | 2024 | |
| Nxstage Medical, INC. | $87.83 | 2024-2025 | Liberty Select Cycler, Nxstage System One |
| Alexion Pharmaceuticals, INC. | $60.90 | 2023 | |
| Opko Pharmaceuticals, LLC | $38.63 | 2020 | |
| Vifor Pharma, INC. | $21.97 | 2020 | |
| Fresenius USA Marketing, INC. | $13.90 | 2022 | |
| Travere Therapeutics, INC. | $4.32 | 2023-2025 | Filspari |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Steer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.